This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Centene's (CNC) Q3 Earnings Beat on Membership Growth?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and lower cost of services.
Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication
by Zacks Equity Research
FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.
Does Jazz (JAZZ) Have the Potential to Rally 47.29% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Ligand (LGND) Acquires Certain Assets of Novan for $12.2M
by Zacks Equity Research
Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
by Zacks Equity Research
The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.
Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View
by Zacks Equity Research
Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.
Why Is Jazz (JAZZ) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
by Zacks Equity Research
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
by Zacks Equity Research
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
Nektar (NKTR) Stock Surges 75% in a Week: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
by Zacks Equity Research
Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.
Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.
Wall Street Analysts See a 51.66% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 51.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Jazz (JAZZ) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 1.12% and 0.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 10% and 2.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season?
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -3.28% and 14.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will High Medical Costs Hurt Cigna (CI) in Q2 Earnings?
by Zacks Equity Research
Cigna's (CI) Q2 results are likely to reflect strength in the specialty pharmacy business and growing medical customer base, partly offset by higher medical expenses.
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 23.38% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Jazz Pharmaceuticals, Oshkosh and StoneCo
by Zacks Equity Research
Jazz Pharmaceuticals, Oshkosh and StoneCo are part of the Zacks top Analyst Blog.